Skip to main content
Figure 3 | Stem Cell Research & Therapy

Figure 3

From: Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes

Figure 3

Total levels and intracellular distributions of K V 7.1 in LQT1 patient-derived human induced pluripotent stem cell cardiomyocytes. (A) Representative western blot image of Kv7.1 (left) and bar graft showing the levels of KV7.1 plotted against β-actin (right). **P <0.01, versus control. (B) Representative images of co-immunofluorescence staining of α-actinin (red) and KV7.1 (green) (left top panel, 63×; scale bar: 20 μM) and Golgi apparatus (red) and Kv7.1 (green) (left middle panel, 63×; scale bar: 20 μM; and left bottom panel, 40×; scale bar: 40 μM) in control and patient human induced pluripotent stem cell cardiomyocytes (hiPSC-CMs). Cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI; blue). The membranous and perinuclear distributions of KV7.1 were quantified in KV7.1 and Golgi apparatus co-staining images by ImageJ software (National Institutes of Health, Bethesda, MD, USA). The relative ratio was plotted and presented in a bar graph (right). **P <0.01, versus control. LQT1, type 1 long QT syndrome.

Back to article page